Aurora Cannabis Inc surprised analysts with a significant earnings beat, but challenges remain in its revenue streams.
Recent earnings trend
Advertisement
Aurora Cannabis Inc
ACB.TO
ACB.TO
Aurora Cannabis Inc
WealthAwesomeAdvertisement
Market cap
$257.06M
52W high
$9.33
52W low
$3.59
1W change
+3.87%
Beta
1.34
Analyst Price Targets
Based on analyst covering ACB
Wall Street analysts forecast ACB stock price to rise 38.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$5.56
+38.0% Upside
Current Price
C$4.03
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ACB's historical volatility
30-Day Vol
36.0%
Annualized
90-Day Vol
47.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.37
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$3.80 | C$3.35 โ C$4.30 |
| 60 trading days | C$3.58 | C$3.00 โ C$4.27 |
| 90 trading days | C$3.37 | C$2.72 โ C$4.18 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 2 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 2 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-04 | โ | -0.0900 | โ |
| 2026-06-30 | 2026-08-05 | -0.0700 | -0.2100 | +66.7% |
| 2026-03-31 | 2026-06-11 | -0.9900 | -0.1400 | -607.1% |
| 2025-12-31 | 2026-02-04 | 0.0300 | -0.0800 | +137.5% |
| 2025-09-30 | 2025-11-05 | -0.9100 | -0.1000 | -810.0% |
| 2025-06-30 | 2025-08-06 | -0.2700 | -0.0200 | -1250.0% |
Advertisement
Aurora Cannabis Inc (ACB.TO) reported its fiscal Q1 2027 earnings on August 5, 2026, revealing an EPS of -$0.07, which surpassed the analysts' estimate of -$0.21 by a notable 66.67%. This marks the second earnings beat in the last four quarters, a positive signal amidst ongoing challenges in the cannabis industry.
Investor takeaway: Investors should note that while Aurora's EPS performance exceeded expectations, the company's revenue decline and strategic shifts suggest a cautious approach moving forward. The focus on international medical markets could be key to future growth.
EPS Surprises by 66.67%, Revenue Declines by 9%
Although Aurora achieved a substantial EPS surprise, the decline in revenue and profit margins highlights ongoing struggles within the company and the broader cannabis market.
Bull case
Aurora's shift towards international medical cannabis markets is showing promise, with a 17% increase in international sales. This focus could help stabilize revenue and improve profitability over time.
Bear case
Despite the earnings beat, Aurora's overall revenue fell by 9%. A significant drop in consumer cannabis sales raises concerns about the company's ability to maintain growth. Additionally, changes in reimbursement rates could further impact Canadian medical sales.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
